When Can We Expect a COVID Vaccine? The CDC Estimates as Soon as Mid-December

Fitness

LAKEWOOD, CALIFORNIA - OCTOBER 14: A nurse administers a flu vaccination shot to a woman at a free clinic held at a local library on October 14, 2020 in Lakewood, California. Medical experts are hoping the flu shot this year will help prevent a 'twindemic'- an epidemic of influenza paired with a second wave of COVID-19 which could lead to overwhelmed hospitals amid the coronavirus pandemic. (Photo by Mario Tama/Getty Images)Image Source: Getty / Mario Tama

Just days after Pfizer reported that its COVID-19 vaccine has proven to be 95 percent effective, Centers For Disease Control and Prevention Director Robert Redfield announced that the vaccine will likely be available “by the end of the second week in December.” According to an interview Redfield did with Fox News, he projects that 40 million doses of the vaccine will be produced before the end of the year. “That’s enough to vaccinate 20 million people,” he said. “But then it will continue through January and February and hopefully by March we’ll start to see vaccine available for the general public.”

Redfield added that, once the medication has been approved, it will be rolled out in a hierarchical manner, prioritizing nursing home residents and healthcare providers. The news may be a relief to millions of households across the country, but Redfield urges the public to continue abiding by the CDC’s recommended COVID-19 safety precautions as we wait for the new vaccine to become widely available. “I want people to be vigilant because we’re turning the corner now,” he said. “You don’t want to be the last group to end up getting COVID.”

Products You May Like

Articles You May Like

Why Americans are outraged over health insurance — and what could change
Dexcom’s over-the-counter glucose monitor now offers users an AI summary of how sleep, meals and more impact sugar levels
Dirty Martini Dip
These Dancers Want to Prove Breaking Isn’t a Joke After the Olympics Memes
Healthy Returns: Novo Nordisk’s Ozempic faces scrutiny over potential link to rare eye condition

Leave a Reply

Your email address will not be published. Required fields are marked *